Get startedLog in
    Picture of Beyondspring logo

    BYSI — Beyondspring News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeMicro CapSucker Stock
    All News

    Drugmaker BeyondSpring's Q3 net loss narrows to $1.7 mln

    Picture of Beyondspring logoBeyondspring
    12/11/2025 12:08
    Overview

BeyondSpring Q3 net loss narrows to $1.7 mln from $2.2 mln last year

Plinabulin shows promising results in NSCLC patients at SITC 2025 presentations

SEED secures $30 mln financing, achieves IND clearance for RBM39 program

Outlook

BeyondSpring emphasizes Plinabulin's potential in resensitizing tumors resistant to checkpoint inhibitors

Company highlights SEED's IND clearance for RBM39 degrader program in the US and China

BeyondSpring focuses on advancing Plinabulin's clinical development for durable survival benefits

Result Drivers

Research and development (R&D) expenses were $1.0 million for the quarter ended September 30, 2025 compared to $0.6 million for the quarter ended September 30, 2024

Key Details


    MetricBeat/MissActualConsensus Estimate
    Q3 Net Income-$1.70 mln
    

Press Release: ID:nGNX29qBv7

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

    Recent news on Beyondspring

    See all news